Scientists have generated human stem cells that in some respects mimic mouse na€ ıve cells, but their dependence on the addition of several extrinsic agents, and their propensity to develop abnormal karyotype calls into question their resemblance to a naturally occurring "na€ ıve" state in humans. Here, we report that a recombinant, truncated human NME7, referred to as NME7 AB here, induces a stable na€ ıve-like state in human embryonic stem cells and induced pluripotent stem cells without the use of inhibitors, transgenes, leukemia inhibitory factor (LIF), fibroblast growth factor 2 (FGF2), feeder cells, or their conditioned media. Evidence of a na€ ıve state includes reactivation of the second X chromosome in female source cells, increased expression of na€ ıve markers and decreased expression of primed state markers, ability to be clonally expanded and increased differentiation potential. RNA-seq analysis shows vast differences between the parent FGF2 grown, primed state cells, and NME7 AB converted cells, but similarities to altered gene expression patterns reported by others generating na€ ıve-like stem cells via the use of biochemical inhibitors. Experiments presented here, in combination with our previous work, suggest a mechanistic model of how human stem cells regulate self-replication: an early na€ ıve state driven by NME7, which cannot itself limit self-replication and a later na€ ıve state regulated by NME1, which limits self-replication when its multimerization state shifts from the active dimer to the inactive hexamer. STEM CELLS 2016;34:847-859
SIGNIFICANCE STATEMENTThe results of these studies argue that a na€ ıve stem cell state does exist in humans and indicates that a naturally occurring growth factor, NME7, supports the earliest na€ ıve state, but is replaced by a related growth factor, NME1, that limits pluripotent growth via changes in its multimerization state. The existence of a na€ ıve state in humans could have a profound effect on the study of basic science and on future stem cell therapies. Na€ ıve stem cells, if they live up to their promise, could streamline low cost, high throughput stem cell production, improve the quality of stem cell derived cells and render genetic editing routine.